Skip to Content
MilliporeSigma
  • Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease.

Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease.

Obstetrics and gynecology (2013-05-03)
Tarayn Fairlie, Elizabeth R Zell, Stephanie Schrag
ABSTRACT

To estimate the effectiveness against early-onset group B streptococcal (GBS) disease of intrapartum antibiotic prophylaxis among term and preterm deliveries, deliveries with fewer than 4 hours of antibiotics, and deliveries receiving clindamycin regimens. We performed a secondary analysis of the Birthnet cohort, a survey of 7,691 births to residents of the Active Bacterial Core surveillance system from 2003 to 2004. We used propensity score matching on covariates associated with prophylaxis and early-onset GBS disease to evaluate the effectiveness (1-risk ratio) of specific intrapartum antibiotic prophylaxis regimens against the disease end point. The effectiveness of 4 or more hours of prophylaxis with penicillin or ampicillin was high among term (91%, 95% confidence interval [CI] +63% to +98%) and preterm (86%, 95% CI +38% to +97%) neonates. Effectiveness was significantly lower for clindamycin (22%, 95% CI -53% to +60%). The effectiveness of 2 or fewer to fewer than 4 hours of prophylaxis with penicillin or ampicillin before delivery (47%, 95% CI -16% to +76%) and the effectiveness of prophylaxis with penicillin or ampicillin fewer than 2 hours before delivery (38%, 95% CI -17% to +67%) were both lower than the effectiveness of prophylaxis durations at 4 or more hours. Beta-lactam prophylaxis given 4 or more hours before delivery is highly effective for prevention of early-onset GBS disease. Prophylaxis of shorter durations or with clindamycin is less effective, reinforcing the need for health care providers to adhere to prevention recommendations, particularly for preterm deliveries, penicillin-allergic women, and neonates exposed to fewer than 4 hours of prophylaxis.

MATERIALS
Product Number
Brand
Product Description

Supelco
Clindamycin hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin sodium salt, BioXtra, suitable for cell culture
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Pricing and availability is not currently available.
Sigma-Aldrich
Clindamycin hydrochloride, lincosamide antibiotic
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin sodium salt
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin sodium salt, powder or crystals, BioReagent, suitable for cell culture
Pricing and availability is not currently available.
Supelco
Ampicillin, analytical standard
Pricing and availability is not currently available.
Clindamycin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Supelco
Ampicillin trihydrate, VETRANAL®, analytical standard
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin trihydrate, 900-1050 μg/mg anhydrous basis (HPLC)
Pricing and availability is not currently available.
Sigma-Aldrich
Ampicillin, meets USP testing specifications
Pricing and availability is not currently available.